论文部分内容阅读
目的 观察环孢素A(cyclosporine,CsA)滴眼液对鼠角膜移植术后免疫排斥反应的治疗效果。方法 随机对纯系大鼠LOU 6 5只为受体及F344纯系大鼠 33只为供体建立的角膜移植术后免疫排斥反应动物模型分为 6组 ,各组分别于手术后滴用 0 5 %CsA、1 0 %CsA、2 0 %CsA、糖皮质激素、糖皮质激素和 1 0 %CsA及CsA基质滴眼液 ,观察角膜移植术后植片排斥反应指数 (rejectionindex,RI) ,植片平均存活时间 (meanssurvivaltime ,MST) ,并对角膜植片进行病理学检查及免疫病理学分析。结果 0 5 %CsA、1 0 %CsA、2 0 %CsA、糖皮质激素及混合组的植片MST均较对照组延长 1 6 3～ 8 46d ,其中 2 0 %CsA组、糖皮质激素组及混合组的植片MST延长与其他组比较差异有显著性 (t≥ 2 2 8,P <0 0 1) ,混合组为 (15 71± 5 0 6 )d。对照组的角膜植片排斥RI较其他组高 ,其中 2 0 %CsA组与糖皮质激素组的角膜植片排斥RI一致 ,分别为 5 34± 1 92和 5 18± 1 6 9;混合组治疗效果最好 ,RI为4 31± 1 5 0 ,而CsA滴眼液治疗后大鼠血清中的浓度介于 2 1 6～ 6 2 2mg/L。病理学检查 :各治疗组角膜植片淋巴细胞浸润减轻 ,新生血管减少 ;免疫病理显示 ,除 0 5 %CsA组外 ,其余各组的淋巴细胞相关抗原 1(LFA 1,CD+11a)、ICAM 1表达和
Objective To observe the effect of cyclosporine (CsA) eye drops on immunological rejection after corneal transplantation in rats. Methods The animals were randomly divided into 6 groups: LOU 6 5 recipients and 33 F344 pure donors. The animal models of rejection after corneal transplantation were divided into 6 groups. The rats in each group were treated with 0 5% CsA, 10% CsA, 20% CsA, glucocorticoids, glucocorticoids and 10% CsA and CsA were used to observe the rejection index (RI) after corneal transplantation Mean survival time (meanssurvivaltime, MST), and pathological examination and immunopathological analysis of corneal graft. Results The MST of 0 5% CsA, 1 0% CsA, 2 0% CsA, glucocorticoid and mixed group were prolonged by 1 36 to 8 46 days compared with control group, of which 20% CsA group, glucocorticoid group and The MST prolongation in the mixed group was significantly different from other groups (t≥2 2 8, P 0 01), and mixed group was (15 71 ± 5 0 6) d. The corneal graft rejection RI in the control group was higher than that in the other groups. The RI of the corneal graft in 20% CsA group and glucocorticoid group were the same (5 34 ± 1 92 and 5 18 ± 1 69 respectively) The best effect was RI = 4 31 ± 150, while the serum concentration of CsA eye drops was 21 6 ~ 62 2 mg / L. Pathological examination: Corneal graft lymphocytes infiltration and neovascularization were reduced in all treatment groups. Immunohistopathology showed that in addition to 0 5% CsA group, lymphocyte-associated antigen 1 (LFA 1, CD + 11a), ICAM 1 expression and